Structure-Based Design of Macrocyclic Coagulation Factor VIIa Inhibitors.

E Scott Priestley, Daniel L Cheney, Indawati DeLucca, Anzhi Wei, Joseph M Luettgen, Alan R Rendina, Pancras C Wong, Ruth R Wexler

Index: J. Med. Chem. 58 , 6225-36, (2015)

Full Text: HTML

Abstract

On the basis of a crystal structure of a phenylpyrrolidine lead and subsequent molecular modeling results, we designed and synthesized a novel series of macrocyclic FVIIa inhibitors. The optimal 16-membered macrocycle was 60-fold more potent than an acyclic analog. Further potency optimization by incorporation of P1' alkyl sulfone and P2 methyl groups provided a macrocycle with TF/FVIIa Ki = 1.6 nM, excellent selectivity against a panel of seven serine proteases, and FVII-deficient prothrombin time EC2x = 1.2 μM. Discovery of this potent, selective macrocyclic scaffold opens new possibilities for the development of orally bioavailable FVIIa inhibitors.